CHOP Collaborates With Pfizer's Centers For Therapeutic Innovation To Speed Pediatric Research & Development
"Working with leading academic researchers is a key part of the CTI model," said Anthony Coyle, Ph.D., CTI's Chief Scientific Officer. "CHOP's world-class reputation as a leading research hospital means it is an ideal partner for CTI as we continue our determined efforts to translate exciting science into effective medicines for patients."
"It's extremely rewarding for our researchers to see their scientific work translated into bedside treatments that directly benefit children," said Ellen Purpus, Ph.D., director of CHOP's Office of Technology Transfer. "This partnership will help to expedite that process."
Ab out The Children's Hospital of Philadelphia The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 516-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
About Pfizer's CTI The Centers for Therapeutic Innovation (CTI) is an entrepreneurial Research Unit at Pfizer, Inc. dedicated to the establishment of partnerships with Academic Medical Centers (AMCs) to transform research and development through a focus on translational medicine. CTI is an open innovation network with 21 leading AMCs focused on joint discovery and development of therapeutics, from early research through clinical proof-of-mechanism in humans. This model offers leading investigators the resources to pursue potential scientific and clinical breakthroughs by providing access to select Pfizer compound libraries, proprietary screening methods and antibody development technologies that are directly relevant to the investigators' work. The aim is to translate scientific ideas into clinically differentiated candidates ready for evaluation in a stratified patient population. CTI laboratories include Pfizer employees working side-by-side with leading investigators and post-doctoral researchers from the AMCs. The CTI collaborative model effectively and efficiently combines the best ideas, research and expertise of the AMCs with Pfizer's experience, technology and resources. For more information about CTI, visit http://www.pfizer.com/research/rd_works/centers_for_therapeutic_innovation.jspAbout Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com Contacts: John Ascenzi The Children's Hospital of Philadelphia Phone: (267) 426-6055 Ascenzi@email.chop.edu Jennifer Kokell Pfizer Inc. (212) 733-2596 Jennifer.kokell@ Pfizer.com SOURCE The Children's Hospital of Philadelphia
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV